Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, randomized, double-blind, cross-over study of S-600918 in subjects with refractory/unexplained chronic cough

Next Previous
Search
Trial Profile

A Phase 2, randomized, double-blind, cross-over study of S-600918 in subjects with refractory/unexplained chronic cough

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sivopixant (Primary)
  • Indications Cough
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shionogi

    • Most Recent Events

    • 14 Oct 2021 Primary endpoint of The rate of change in hourly cough frequency during the daytime from the baseline to two weeks after administration of the study agenthas not been met.(Efficacy)Results published in the European Respiratory Journal
    • 14 Oct 2021 Results published in the European Respiratory Journal
    • 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top